The next-gen GLP-1 horizon: orforglipron, CagriSema, MariTide, and which to actually wait for

The GLP-1 horizon has gotten busier. Orforglipron just received FDA approval as Foundayo in April 2026. CagriSema is reading out phase 3 trials this quarter. MariTide is in phase 3 with a different mechanism. Three different bets on what comes after tirzepatide and semaglutide.

The reader question I get most: should I wait for one of these instead of starting tirzepatide now?

For most readers the answer is no. For a small subset, the wait might be defensible. Here's the honest read on each.

Orforglipron (Foundayo): already here

Lilly's oral small-molecule GLP-1 received FDA approval on April 1, 2026 under the National Priority Voucher program. 50 days from filing to approval, 294 days ahead of the January 2027 PDUFA date that had been expected.

The data:

ATTAIN-1, the 72-week trial in 3,127 adults with obesity (no diabetes), reported 12.4% mean weight reduction at the 36mg high dose versus 0.9% on placebo. ATTAIN-2 in T2D + obesity reported 10.5% at the high dose at 72 weeks.

What this is, mechanically:

Not a peptide despite the name. Orforglipron is an oral small-molecule GLP-1 receptor agonist. No injection. No cold chain. No food or water restriction (unlike Rybelsus, the existing oral semaglutide, which requires fasting administration and has very low bioavailability).

What this means for you:

If you've been considering injectables and the injection is your blocker, orforglipron solves that problem. If you've been on Rybelsus and finding the fasting requirement annoying, orforglipron is more convenient.

What this doesn't change:

Tirzepatide produces 18-25% weight loss at full dose. Orforglipron produces 12.4%. They're not in the same efficacy tier. If maximum weight loss is your goal, tirzepatide is still the answer. If injection avoidance is your goal, orforglipron is now a real option.

The supply story is also fundamentally different. Small-molecule manufacturing scales differently from peptide synthesis. Multiple contract manufacturers, shorter lead times, geographically distributed capacity. The supply bottlenecks that defined the 2023-2025 GLP-1 era should unwind for orforglipron faster than for tirzepatide or semaglutide.

Verdict: Already approved, available now. Worth considering if you specifically need oral and don't need maximum efficacy.

CagriSema: phase 3 reading out this year

Novo Nordisk's combination of cagrilintide (an amylin analog) plus semaglutide. Sometimes positioned as Novo's answer to tirzepatide.

The data so far:

Phase 2 trials showed 15-17% weight loss at 32-68 weeks. The REDEFINE-1 phase 3 trial in obesity (no diabetes) is reading out partial data this quarter; the full readout is expected late 2026.

The mechanism:

Cagrilintide targets the amylin receptor (a different pathway than GLP-1). The combination with semaglutide produces a dual-mechanism effect similar in concept to tirzepatide's GLP-1 + GIP, but pharmacologically distinct.

What this might mean:

If REDEFINE-1 readouts show CagriSema producing weight loss in the 18-22% range, it's a real tirzepatide alternative for Novo's customers. If the readout is closer to 15%, it's modest improvement over Wegovy alone (15% in STEP-1) but not a tier-jump.

The patient population question:

CagriSema combines two molecules into one product. Patients who tolerated semaglutide but want more efficacy are the obvious target. Patients who tolerated tirzepatide are unlikely to switch.

Verdict: Worth waiting for the phase 3 readout if you're already on Wegovy and asking whether to escalate to tirzepatide vs wait for CagriSema. If you're treatment-naive, don't wait. Start whatever your prescriber recommends now, switch later if CagriSema's data justifies it.

MariTide: phase 3, longer tail

Amgen's monoclonal antibody-peptide conjugate. GIP receptor antagonist + GLP-1 receptor agonist. Genuinely different mechanism than tirzepatide's GIP + GLP-1 dual agonism.

The data so far:

Phase 2 showed roughly 17% weight loss with monthly dosing (vs weekly for tirzepatide and semaglutide). Phase 3 is in progress; readout expected mid-2027.

What's interesting:

Monthly dosing is genuinely different. The compliance and convenience implications are real. Monthly dosing also produces different pharmacokinetics, flatter peaks and troughs, less of the "appetite returns mid-week" pattern some patients on weekly dosing experience.

What's unproven:

The GIP antagonist arm is the bet. Tirzepatide's GIP agonist arm contributes to its weight-loss superiority over semaglutide (the GIP receptor activation enhances satiety and energy expenditure). MariTide bets that ANTAGONIZING the GIP receptor produces equal or better weight loss through a different downstream mechanism.

This is biologically counterintuitive. The phase 2 data supports it. Phase 3 will tell us whether the result holds in a larger population.

Verdict: Don't wait. Even a fast track gets MariTide to approval no earlier than late 2027 to mid-2028. By the time it's available, you'd have already spent 18-24 months on tirzepatide and either stabilized or stopped. The waiting cost is high; the potential upside is uncertain.

Retatrutide: the dark horse

Lilly's triple agonist (GLP-1 + GIP + glucagon). Phase 2 data showed 24% weight loss at 48 weeks, the most impressive single-trial result in the class. Phase 3 trials are ongoing; first readout (TRIUMPH-1) expected late 2026, but the cardiovascular outcomes trial (TRIUMPH-3) won't complete until 2028.

Where this fits:

Retatrutide is the highest-efficacy candidate in the pipeline, but its complexity (three receptor targets) creates more uncertainty about side-effect profile in larger populations. The glucagon receptor activation specifically has implications for blood glucose, hepatic effects, and cardiovascular safety that need the larger trials to characterize.

Verdict: Still 18+ months from any approval. Same waiting-cost argument as MariTide. Watch the readouts; don't plan around availability.

What I'd actually tell readers asking "should I wait?"

If you're at decision point on starting GLP-1 today:

Don't wait for any of the horizon drugs unless one of these specific conditions applies:

1. You specifically need oral over injectable and you've already tried Rybelsus → wait briefly for orforglipron access in your region (it's already approved, supply ramping).

2. You're already on Wegovy and considering escalation to tirzepatide → wait 3-6 months for CagriSema phase 3 readouts. If CagriSema lands in the 18%+ range, it's a defensible alternative; if it lands at 15-16%, escalate to tirzepatide.

3. You can wait 18-24 months and aren't experiencing meaningful health consequences from the current weight → wait for MariTide or retatrutide phase 3. The efficacy gap might justify the wait.

For everyone else: start with what's approved and works (tirzepatide is currently the highest-efficacy approved option, semaglutide if cost is the constraint, orforglipron if oral is required). The drugs in the pipeline aren't going to obsolete the current standard of care; they'll add options. You can switch later if the data justifies.

The waiting cost is real. The metabolic improvements from 18-24 months on a current-generation GLP-1 are worth more than incremental efficiency from the next-generation drug. The patients who waited two years for Wegovy when Ozempic was already prescribable for off-label weight loss missed two years of benefit. The same calculus applies now.

For the broader compound landscape: the FDA horizon piece covers what else is moving. The peptide-pulse digest tracks the monthly state.